S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
Teva Pharma is the way to play the re-rise of generic drugs
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
BellRing Brands gets pumped on the Ozempic weight-loss trend
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
Teva Pharma is the way to play the re-rise of generic drugs
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
BellRing Brands gets pumped on the Ozempic weight-loss trend
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
Teva Pharma is the way to play the re-rise of generic drugs
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
BellRing Brands gets pumped on the Ozempic weight-loss trend
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
Teva Pharma is the way to play the re-rise of generic drugs
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
BellRing Brands gets pumped on the Ozempic weight-loss trend
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.

REGENXBIO Stock Price, News & Analysis (NASDAQ:RGNX)

$19.19
-0.31 (-1.59%)
(As of 11/27/2023 ET)
Compare
Today's Range
$18.63
$19.45
50-Day Range
$12.89
$20.03
52-Week Range
$12.82
$25.54
Volume
279,638 shs
Average Volume
579,697 shs
Market Capitalization
$844.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.13

REGENXBIO MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
62.2% Upside
$31.13 Price Target
Short Interest
Bearish
10.40% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.98) to ($2.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

268th out of 935 stocks

Biological Products, Except Diagnostic Industry

40th out of 161 stocks


RGNX stock logo

About REGENXBIO Stock (NASDAQ:RGNX)

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. In addition, it also develops RGX-121 for the treatment of mucopolysaccharidosis type II and is in Phase III clinical trial; RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. Further, the company also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

RGNX Stock Price History

RGNX Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Earnings Preview For Regenxbio
Regenxbio: Promising Yet Risky Therapeutic Horizon
OMEE, TNDM and RGNX are among after hour movers
See More Headlines
Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
11/28/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RGNX
Fax
N/A
Employees
401
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.13
High Stock Price Target
$55.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+62.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$-280,320,000.00
Net Margins
-262.18%
Pretax Margin
-262.23%

Debt

Sales & Book Value

Annual Sales
$99.37 million
Book Value
$11.92 per share

Miscellaneous

Free Float
38,009,000
Market Cap
$844.21 million
Optionable
Optionable
Beta
1.12
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Kenneth T. MillsMr. Kenneth T. Mills (Age 48)
    President, CEO & Director
    Comp: $1.02M
  • Mr. Vittal K. Vasista (Age 55)
    Executive VP & CFO
    Comp: $671.41k
  • Mr. Curran M. Simpson M.S. (Age 61)
    Executive VP & COO
    Comp: $677.7k
  • Dr. Olivier Danos Ph.D. (Age 65)
    Executive VP & Chief Scientific Officer
    Comp: $728.06k
  • Dr. Stephen Pakola M.D. (Age 54)
    Executive VP & Chief Medical Officer
    Comp: $673.76k
  • Mr. Patrick J. Christmas II (Age 52)
    J.D., Executive VP & Chief Legal Officer
    Comp: $1.11M
  • Ms. Shiva G. Fritsch
    Chief Communications & People Officer
  • Dr. Laura A. Coruzzi J.D. (Age 69)
    Ph.D., Executive Vice President of Intellectual Property
  • Dr. Ram Palanki Pharm.D. (Age 47)
    Executive VP of Commercial Strategy & Operations
  • Dr. Stephen Yoo M.D. (Age 45)
    Consultant
    Comp: $573.71k














RGNX Stock Analysis - Frequently Asked Questions

Should I buy or sell REGENXBIO stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RGNX shares.
View RGNX analyst ratings
or view top-rated stocks.

What is REGENXBIO's stock price target for 2024?

8 brokerages have issued 1 year price objectives for REGENXBIO's stock. Their RGNX share price targets range from $14.00 to $55.00. On average, they anticipate the company's stock price to reach $31.13 in the next twelve months. This suggests a possible upside of 62.2% from the stock's current price.
View analysts price targets for RGNX
or view top-rated stocks among Wall Street analysts.

How have RGNX shares performed in 2023?

REGENXBIO's stock was trading at $22.68 on January 1st, 2023. Since then, RGNX shares have decreased by 15.4% and is now trading at $19.19.
View the best growth stocks for 2023 here
.

When is REGENXBIO's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our RGNX earnings forecast
.

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) announced its quarterly earnings data on Wednesday, November, 8th. The biotechnology company reported ($1.41) EPS for the quarter, beating the consensus estimate of ($1.44) by $0.03. The biotechnology company had revenue of $28.90 million for the quarter, compared to the consensus estimate of $26.14 million. REGENXBIO had a negative net margin of 262.18% and a negative trailing twelve-month return on equity of 59.54%. The firm's revenue for the quarter was up 9.1% on a year-over-year basis. During the same period last year, the business posted ($1.75) earnings per share.

What ETFs hold REGENXBIO's stock?

ETFs with the largest weight of REGENXBIO (NASDAQ:RGNX) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among the company's employees.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Block (SQ).

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by a number of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (8.33%), Redmile Group LLC (5.85%), Jacobs Levy Equity Management Inc. (1.28%), Northern Trust Corp (0.98%), Bank of New York Mellon Corp (0.82%) and Charles Schwab Investment Management Inc. (0.74%). Insiders that own company stock include Allan M Fox, Curran Simpson, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends
.

How do I buy shares of REGENXBIO?

Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RGNX) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -